Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:CVM NASDAQ:MGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCel-Sci$1.43+10.0%$3.33$0.89▼$13.48$12.14M0.7204,923 shs1.11 million shsMGTXMeiraGTx$9.40-5.5%$8.83$4.82▼$11.85$870.16M1.23601,627 shs768,589 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCel-Sci+8.33%-18.75%-70.18%-73.47%-82.03%MGTXMeiraGTx-0.20%+2.79%-11.87%+33.56%+114.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCel-Sci$1.43+10.0%$3.33$0.89▼$13.48$12.14M0.7204,923 shs1.11 million shsMGTXMeiraGTx$9.40-5.5%$8.83$4.82▼$11.85$870.16M1.23601,627 shs768,589 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCel-Sci+8.33%-18.75%-70.18%-73.47%-82.03%MGTXMeiraGTx-0.20%+2.79%-11.87%+33.56%+114.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVMCel-Sci 0.00N/AN/AN/AMGTXMeiraGTx 2.75Moderate Buy$25.83174.82% UpsideCurrent Analyst Ratings BreakdownLatest MGTX and CVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $25.004/22/2026MGTXMeiraGTx Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $30.004/21/2026MGTXMeiraGTx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $24.003/27/2026MGTXMeiraGTx Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $26.003/27/2026MGTXMeiraGTx Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $16.003/27/2026MGTXMeiraGTx Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.003/9/2026MGTXMeiraGTx Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVMCel-SciN/AN/AN/AN/A$2.32 per shareN/AMGTXMeiraGTx$81.39M10.69N/AN/A($0.07) per share-134.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVMCel-Sci-$25.41M-$9.77N/AN/AN/AN/A-226.09%-102.18%N/AMGTXMeiraGTx-$114.20M-$1.42N/AN/AN/A-140.31%-1,065.47%-53.33%N/ALatest MGTX and CVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026CVMCel-SciN/A-$0.67N/A-$0.67N/AN/A5/14/2026Q1 2026MGTXMeiraGTx-$0.58-$0.57+$0.01-$0.57$17.00 million$0.29 million3/26/2026Q4 2025MGTXMeiraGTx-$0.60$0.19+$0.79$0.19$3.87 million$75.36 million2/17/2026Q1 2026CVMCel-SciN/A-$0.68N/A-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVMCel-SciN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVMCel-Sci0.451.391.35MGTXMeiraGTxN/A0.750.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVMCel-Sci12.08%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipCVMCel-Sci9.93%MGTXMeiraGTx7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVMCel-Sci438.49 million7.65 millionOptionableMGTXMeiraGTx30092.57 million85.63 millionOptionableMGTX and CVM HeadlinesRecent News About These CompaniesMeiraGTx (NASDAQ:MGTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysMay 15 at 10:20 AM | marketbeat.comMeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 15 at 5:05 AM | seekingalpha.comMeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 14 at 4:30 PM | globenewswire.comMeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue EstimatesMay 14 at 10:10 AM | zacks.comMeiraGTx Reports First Quarter 2026 Financial and Operational ResultsMay 14 at 8:00 AM | globenewswire.comMeiraGTx (MGTX) Projected to Post Earnings on TuesdayMay 10, 2026 | americanbankingnews.comMeiraGTx (MGTX) Projected to Post Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comWill MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should KnowMay 5, 2026 | zacks.comMeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 5, 2026 | marketbeat.comMeiraGTx (NASDAQ:MGTX) Stock Price Expected to Rise, Piper Sandler Analyst SaysApril 22, 2026 | marketbeat.comWhat is HC Wainwright's Forecast for MeiraGTx Q1 Earnings?April 22, 2026 | marketbeat.comRichard Giroux Sells 56,000 Shares of MeiraGTx (NASDAQ:MGTX) StockApril 21, 2026 | marketbeat.comMeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?April 20, 2026 | zacks.comEvercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector RevisionsApril 18, 2026 | finance.yahoo.comMeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume on Analyst UpgradeApril 18, 2026 | defenseworld.netDMeiraGTx (NASDAQ:MGTX) Sees Unusually-High Trading Volume on Analyst UpgradeApril 17, 2026 | marketbeat.comRoyal Bank Of Canada Issues Positive Forecast for MeiraGTx (NASDAQ:MGTX) Stock PriceApril 17, 2026 | marketbeat.comMeiraGTx reacquires bota-vec rights and prices public offeringApril 16, 2026 | thepharmaletter.comTEli Lilly partner MeiraGTx regains rights for genetic eye disease drug from Johnson & JohnsonApril 16, 2026 | msn.comMeiraGTx eyes $100M equity offering after gene therapy deal with J&JApril 16, 2026 | msn.comMeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity TranscriptApril 16, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGTX and CVM Company DescriptionsCel-Sci NYSEAMERICAN:CVM$1.43 +0.13 (+10.00%) Closing price 04:10 PM EasternExtended Trading$1.46 +0.03 (+1.75%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.MeiraGTx NASDAQ:MGTX$9.40 -0.55 (-5.53%) Closing price 04:00 PM EasternExtended Trading$9.40 0.00 (0.00%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
